Targeted therapies with chemoradiation in esophageal cancer: Development and future directions

Seminars in Radiation Oncology

Volumn 23, Issue 1, 2013, Pages 31-37

  Hong, Theodore S ^a   Wo, Jennifer Y ^a   Kwak, Eunice L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HEAT SHOCK PROTEIN 90; IRINOTECAN; PACLITAXEL; PANITUMUMAB; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SONIC HEDGEHOG PROTEIN; SORAFENIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VASCULOTROPIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; DRUG EFFICACY; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; HUMAN; METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; STOMACH NEOPLASMS;

EID: 84874415026     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.09.004     Document Type: Article

References (54)

1. van Hagen P., Hulshof M.C., van Lanschot J.J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
2. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
3. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 99102. J Clin Oncol 2007, 25:1160-1168.
4. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
5. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
6. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
7. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
8. Janjigian Y.Y., Werner D., Pauligk C., et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann Oncol 2012, 23:2656-2662.
9. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
10. Safran H., Dipetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 67:405-409.
11. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
12. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24:5201-5206.
13. Shah M.A., Jhawer M., Ilson D.H., et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29:868-874.
14. Enzinger PC, Ryan DP, Regan E, et al: Phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab in patients with metastatic esophagogastric cancer (abstract 97). Presented at the 2008 Gastrointestinal Cancers Symposium, January 25, 2008, San Francisco, CA.
15. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29:3968-3976.
16. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
17. Meluch A.A., Bendell J.C., Peyton J.D., et al. A phase II study of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer. J Clin Oncol 2010, 28(suppl 15). Abstract 1408.
18. Ilson D., Goodman K.A., Janjiigian Y.Y., et al. Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma. J Clin Oncol 2012, 20(suppl 4). Abstract 67.
19. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
20. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
21. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
22. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
23. Yonemura Y., Sugiyama K., Fujimura T., et al. Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology 1989, 46:158-161.
24. Kim J.S., Kim M.A., Kim T.M., et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: Epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 2009, 100:732-738.
25. Pinto C., Di Fabio F., Cascinu S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18:510-517.
26. Enzinger P.C., Burtness B., Hollis D., et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010, 15S:4006.
27. Waddell T.S., Chau I., Barbachano Y., et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 2012, 30S. LBA4000.
28. Safran H., Suntharalingam M., Dipetrillo T., et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity. Int J Radiat Oncol Biol Phys 2008, 70:391-395.
29. Ruhstaller T., Pless M., Dietrich D., et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 2011, 29:626-631.
30. Kleinberg L.R., Catalano P.J., Gibson M.K., et al. ECOG 2205: A phase II study to measure response rate and toxicity of neo-adjuvant chemoradiotherapy (CRT) (IMRT permitted) with oxaliplatin and infusional 5-fluorouracil plus cetuximab in patients with operable adenocarcinoma of the esophagus: High risk of post-op adult respiratory distress syndrome. Int J Radiat Oncol Biol Phys 2010, 78:S72.
31. Hurt C.N., Nixon L.S., Griffiths G.O., et al. SCOPE1: A randomized phase II/III multicenter clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the esophagus. BMC Cancer 2011, 11:466-476.
32. Blackwell K.L., Miles D., Gianni L., et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. J Clin Oncol 2012, 30S. LBA1.
33. Barok M., Tanner M., Köninki K., et al. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011, 306:171-179.
34. Sun W., Powell M., O'Dwyer P.J., et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010, 28:2947-2951.
35. Ilson D., Janjigian Y.Y., Shah M.A., et al. Phase II trial of sorafenib in esophageal and gastroesophageal junction cancer: Response and protracted stable disease observed in adenocarcinoma. J Clin Oncol 2011, 29S:4100.
36. Trusolino L., Bertotti A., Comoglio P.M. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010, 11:834-848.
37. Eder J.P., Vande Woude G.F., Boerner S.A., et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009, 15:2207-2214.
38. Birchmeier C., Birchmeier W., Gherardi E., et al. MET, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.
39. Xin X., Yang S., Ingle G., et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001, 158:1111-1120.
40. Smolen G.A., Sordella R., Muir B., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006, 103:2316-2321.
41. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
42. Turke A.B., Zejnullahu K., Wu Y.L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
43. Ou S.H., Kwak E.L., Siwak-Tapp C., et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011, 6:942-946.
44. Ma P.C., Tretiakova M.S., MacKinnon A.C., et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008, 47:1025-1037.
45. Ma P.C., Tretiakova M.S., Nallasura V., et al. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: Implications for tumour invasion. Br J Cancer 2007, 97:368-377.
46. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
47. Lennerz J.K., Kwak E.L., Ackerman A., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011, 29:4803-4810.
48. Oliner K.S., Tang R., Anderson A., et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. J Clin Oncol 2012, 30S:4005.
49. Whitesell L., Lindquist S.L. Hsp90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
50. Wu X., Wanders A., Wardega P., et al. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 2009, 100:334-343.
51. Yauch R.L., Gould S.E., Scales S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
52. Hidalgo M., Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009, 361:2094-2096.
53. Sims-Mourtada J., Izzo J.G., Apisarnthanarax S., et al. Hedgehog: An attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 2006, 12:6565-6572.
54. Ajani J.A., Wang X., Maru D., et al. Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy with high specificity and desirable sensitivity levels in patients with esophageal cancer. J Clin Oncol 2011, 29S:4027.